AptarGroup acquires Mod3 Pharma’s clinical trial manufacturing capabilities

Aptar Pharma (ATR) announced it has acquired the clinical trial materials manufacturing capabilities of Mod3 Pharma from SWK Holdings (SWKH). The acquisition enhances Aptar’s support for early-stage drug development by providing formulation, fill and finish services for Phase 1 and 2 clinical trials. Through the deal, Aptar Pharma will operate an FDA-inspected facility in Boonton, New Jersey, with an initial focus on orally inhaled nasal drug products. Financial terms were not disclosed.